Scarica l'app Stockscreener
284.91
1.21%
-3.49
Dopo l'orario di chiusura:
284.91
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$288.40
Aprire:
$286.25
Volume 24 ore:
567.36K
Relative Volume:
0.72
Capitalizzazione di mercato:
$20.05B
Reddito:
$2.20B
Utile/perdita netta:
$402.20M
Rapporto P/E:
51.24
EPS:
5.56
Flusso di cassa netto:
$280.80M
1 W Prestazione:
-1.83%
1M Prestazione:
-5.03%
6M Prestazione:
+2.35%
1 anno Prestazione:
+44.44%
Intervallo 1D:
$282.75
$287.40
Intervallo di 1 settimana:
$282.75
$300.24
Portata 52W:
$173.00
$329.33
Insulet Corporation Stock (PODD) Company Profile
Nome
Insulet Corporation
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Confronta PODD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
284.91 | 20.30B | 2.20B | 402.20M | 280.80M | 5.56 |
|
ABT
Abbott Laboratories
|
127.29 | 219.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.41 | 155.22B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
377.79 | 150.09B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
89.34 | 115.62B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.33 | 46.52B | 5.69B | 4.15B | 623.10M | 6.95 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corporation Borsa (PODD) Ultime notizie
Does Insulet Corporation stock perform well during market downturnsOutstanding capital appreciation - jammulinksnews.com
How does Insulet Corporation compare to its industry peersBuild wealth steadily with smart trading - jammulinksnews.com
What is the dividend policy of Insulet Corporation stockDynamic investment growth - jammulinksnews.com
What makes Insulet Corporation stock price move sharplyFind the best stocks for sustainable growth - jammulinksnews.com
Is Insulet Corporation a growth stock or a value stockDiscover high-impact investment opportunities - jammulinksnews.com
What institutional investors are buying Insulet Corporation stockFree Buy/Sell Signal Notifications - jammulinksnews.com
What drives Insulet Corporation stock priceGet real-time alerts on top-performing stocks - jammulinksnews.com
What catalysts could drive Insulet Corporation stock higher in 2025Free Expert Stock Watchlist - jammulinksnews.com
What analysts say about Insulet Corporation stockRapid growth opportunities - jammulinksnews.com
How many analysts rate Insulet Corporation as a “Buy”Get timely market insights for better trades - jammulinksnews.com
Stock Analysis | Insulet OutlookA Mixed Picture Amid Strong Fundamentals and Weak Technicals - AInvest
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks? - MSN
What is Insulet Corporation company’s growth strategyMarket Forecast Opportunities Backed By Experts - jammulinksnews.com
Insulet Corporation Stock (PODD) Opinions on Analyst 'Moderate Buy' Rating - Quiver Quantitative
What to Expect From Insulet's Q2 2025 Earnings Report - MSN
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Diabetes Care Devices Market Size Projects USD 76.44 Billion by 2034 - GlobeNewswire Inc.
Why Insulet Corporation stock attracts strong analyst attentionAI Driven Entry Signal Review - beatles.ru
Insulet Corporation Company Revenue and Profit Trends: A Deep DiveLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Is Insulet (NASDAQ:PODD) Using Too Much Debt? - 富途牛牛
Insulet Corporation Flashes Buy Signal on Multi Timeframe ChartPrice Action Based Buy Opportunity List Published - metal.it
Fibonacci Retracement Aligns with Support in Insulet CorporationCapital Efficiency Optimized Stock Alerts Reviewed - metal.it
Insulet Corporation Sees Spike in Bullish Option FlowTechnical Stock Breakout Predictions Signal Entry Points - metal.it
What are the latest earnings results for Insulet CorporationTrack top-performing stocks in real-time - jammulinksnews.com
Why is Insulet Corporation stock attracting strong analyst attentionUnlock real-time stock alerts for quick profits - jammulinksnews.com
What are the technical indicators suggesting about Insulet CorporationFree Real-Time Stock Data - jammulinksnews.com
Is Insulet Corporation stock overhyped or has real potentialTremendous gains - jammulinksnews.com
Is Insulet Corporation a good long term investmentRapid wealth accumulation - PrintWeekIndia
What institutions are buying Insulet Corporation stock nowExplosive portfolio gains - jammulinksnews.com
Insulet Corporation Q2 2025 Earnings Preview: Anticipating Significant GrowthNews and Statistics - IndexBox
What To Expect From Insulet's Q2 2025 Earnings Report - Barchart.com
Tubeless Insulin Pumps Market Attracts Startups Amid Booming - openPR.com
Insulin Pumps Market Outlook Report 2025, with Leading - GlobeNewswire
EOFlow’s 'EOPatch' Sales Banned in Europe - Businesskorea
Insulet granted EU-wide injunction against EOFlow in default decision by UPC - MLex
Insulet Corporation Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.17%
1.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):